ATE463506T1 - Mit clostriedientoxin aktivierbare clostridientoxine - Google Patents

Mit clostriedientoxin aktivierbare clostridientoxine

Info

Publication number
ATE463506T1
ATE463506T1 AT06851349T AT06851349T ATE463506T1 AT E463506 T1 ATE463506 T1 AT E463506T1 AT 06851349 T AT06851349 T AT 06851349T AT 06851349 T AT06851349 T AT 06851349T AT E463506 T1 ATE463506 T1 AT E463506T1
Authority
AT
Austria
Prior art keywords
clostridial toxins
clostridial
toxins
activated
clostridial toxin
Prior art date
Application number
AT06851349T
Other languages
English (en)
Inventor
Lance Steward
Melvin Oka
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38659164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE463506(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE463506T1 publication Critical patent/ATE463506T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT06851349T 2005-09-19 2006-09-14 Mit clostriedientoxin aktivierbare clostridientoxine ATE463506T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71861605P 2005-09-19 2005-09-19
PCT/US2006/035936 WO2008008082A2 (en) 2005-09-19 2006-09-14 Clostridial toxin activatable clostridial toxins

Publications (1)

Publication Number Publication Date
ATE463506T1 true ATE463506T1 (de) 2010-04-15

Family

ID=38659164

Family Applications (2)

Application Number Title Priority Date Filing Date
AT09175360T ATE518882T1 (de) 2005-09-19 2006-09-14 Mit clostridientoxin aktivierbare clostridientoxine
AT06851349T ATE463506T1 (de) 2005-09-19 2006-09-14 Mit clostriedientoxin aktivierbare clostridientoxine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT09175360T ATE518882T1 (de) 2005-09-19 2006-09-14 Mit clostridientoxin aktivierbare clostridientoxine

Country Status (10)

Country Link
US (4) US7556817B2 (de)
EP (3) EP2377881B1 (de)
JP (1) JP5134540B2 (de)
AT (2) ATE518882T1 (de)
AU (1) AU2006339490B2 (de)
CA (1) CA2610103A1 (de)
DE (1) DE602006013481D1 (de)
DK (2) DK2154151T3 (de)
ES (2) ES2369558T3 (de)
WO (1) WO2008008082A2 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223577B2 (en) 2000-11-17 2007-05-29 Allergan, Inc. Post-translational modifications and Clostridial neurotoxins
US7332567B2 (en) * 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US7374896B2 (en) * 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
US8022172B2 (en) * 2001-08-28 2011-09-20 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
WO2006014899A2 (en) 2004-07-26 2006-02-09 Dow Global Technologies Inc. Process for improved protein expression by strain engineering
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
DK2154151T3 (da) * 2005-09-19 2011-09-05 Allergan Inc Clostridiumtoksinaktiverbare clostridiumtoksiner
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
AU2008245696B2 (en) 2007-04-27 2013-11-07 Pelican Technology Holdings, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
JP5799397B2 (ja) 2008-06-12 2015-10-28 イプセン・バイオイノベーション・リミテッドＩｐｓｅｎ Ｂｉｏｉｎｎｏｖａｔｉｏｎ Ｌｉｍｉｔｅｄ 癌の抑制
EP2719392B1 (de) 2008-06-12 2019-07-24 Ipsen Bioinnovation Limited Fusionproteine zur Verwendung bei der Behandlung von Akromegalie
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
CN105833254A (zh) 2008-12-10 2016-08-10 阿勒根公司 梭菌毒素药物组合物
US8492109B2 (en) * 2009-01-20 2013-07-23 Trustees Of Tufts College Methods for the delivery of toxins or enzymatically active portions thereof
EP2218783A1 (de) 2009-02-05 2010-08-18 Merz Pharma GmbH & Co. KGaA Neuartiges Verfahren zur Herstellung von Neurotoxinen
US8440204B2 (en) * 2009-04-30 2013-05-14 Wisconsin Alumni Research Foundation Subtype of Closteridium botulinum neurotoxin type A and uses thereof
US20130122043A1 (en) * 2010-04-20 2013-05-16 Whitehead Institute For Biomedical Research Modified polypeptides and proteins and uses thereof
EP2571509B1 (de) * 2010-05-20 2016-07-06 Allergan, Inc. Abbaubare clostridientoxine
CA2807488A1 (en) 2010-08-11 2012-02-16 Merz Pharma Gmbh & Co. Kgaa Selective manufacture of recombinant neurotoxin polypeptides
WO2012109387A1 (en) 2011-02-08 2012-08-16 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
WO2012123370A1 (en) 2011-03-11 2012-09-20 Merz Pharma Gmbh & Co. Kgaa Method for the determination of botulinum neurotoxin biological activity
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
US9217172B2 (en) 2011-09-29 2015-12-22 Cellsnap, Llc Compositions and methods for toxigenicity testing
JP2015509372A (ja) 2012-03-07 2015-03-30 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー 修飾ルシフェラーゼに基づいて神経毒活性を測定するための手段および方法
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
US20160289731A1 (en) 2012-11-21 2016-10-06 Merz Pharma Gmbh & Co, Kgaa Means and methods for determination of botulinum neurotoxin biological activity
KR102083371B1 (ko) 2012-11-21 2020-03-04 입센 바이오이노베이션 리미티드 단백질 가수분해 처리된 폴리펩티드의 제조방법
JP6608357B2 (ja) 2013-06-28 2019-11-20 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー 細胞において神経毒ポリペプチドの生物活性を決定する手段及び方法
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
JP6772138B2 (ja) 2014-12-19 2020-10-21 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー 細胞内のＢｏＮＴ／Ｅの生物学的活性を決定するための手段及び方法
EP3242884B1 (de) 2015-01-09 2021-02-24 Ipsen Bioinnovation Limited Kationische neurotoxine
EP3341392A4 (de) 2015-08-27 2019-01-23 President and Fellows of Harvard College Zusammensetzungen und verfahren zur schmerzbehandlung
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
WO2018039506A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Engineered botulinum neurotoxin
RU2019110875A (ru) 2016-09-13 2020-10-15 Аллерган, Инк. Небелковые композиции клостридиального токсина
TW201814045A (zh) 2016-09-16 2018-04-16 英商艾普森生物製藥有限公司 製造雙鏈梭狀芽孢桿菌神經毒素之方法
US20210277071A1 (en) 2016-09-29 2021-09-09 Ipsen Biopharm Limited Hybrid neurotoxins
EP3312290A1 (de) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Zellulärer vamp-spaltungstest
GB201702500D0 (en) * 2017-02-16 2017-04-05 Univ Sheffield Stable vamp reporter assay
TWI810228B (zh) 2017-12-20 2023-08-01 英商艾普森生物製藥有限公司 自主神經系統障礙之治療
EP3752128A1 (de) * 2018-02-16 2020-12-23 Bontana Therapies Gmbh Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung
WO2019224184A1 (en) 2018-05-21 2019-11-28 Ipsen Biopharm Limited Suppression of bone cancer-induced allodynia
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
GB201815844D0 (en) 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
US20220016221A1 (en) 2018-12-05 2022-01-20 Ipsen Biopharm Limited Treatment of symptoms of traumatic brain injury
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
GB201914034D0 (en) 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
GB202001353D0 (en) 2020-01-31 2020-03-18 Ipsen Biopharm Ltd Treatment of skin conditions
KR20220154738A (ko) 2020-03-16 2022-11-22 입센 바이오팜 리미티드 사지 경직을 치료하기 위한 변형된 보툴리눔 신경독소
GB202003813D0 (en) 2020-03-16 2020-04-29 Ipsen Biopharm Ltd Treatment of upper facial lines
GB202011055D0 (en) 2020-07-17 2020-09-02 Ipsen Bioinnovation Ltd Treatment of post-operative pain
GB202015618D0 (en) 2020-10-01 2020-11-18 Ipsen Biopharm Ltd Method for producing beta-trypsin
WO2022140249A1 (en) * 2020-12-21 2022-06-30 Children's Medical Center Corporation Improved receptor-binding domain of botulinum neurotoxin a and uses thereof
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
AU2021438810A1 (en) 2021-03-30 2023-09-21 Ipsen Biopharm Limited Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders
AU2022247196A1 (en) 2021-03-30 2023-10-05 Ipsen Biopharm Limited Treatment of pain & inflammatory disorders
WO2023041934A1 (en) 2021-09-16 2023-03-23 Ipsen Biopharm Limited Modified bont/a for use in the treatment of cervical dystonia
GB202113602D0 (en) 2021-09-23 2021-11-10 Ipsen Biopharm Ltd Treatment of a disorder affecting an eyelid muscle of a subject
WO2023047127A1 (en) 2021-09-23 2023-03-30 Ipsen Biopharm Limited Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
WO2023089343A1 (en) 2021-11-22 2023-05-25 Ipsen Biopharm Limited Treatment of pain
GB202206353D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of cervical dystonia
GB202206361D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of a facial dystonia
GB202206348D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of limb spasticity
GB202206362D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of upper facial lines
GB202213479D0 (en) 2022-09-14 2022-10-26 Ipsen Biopharm Ltd Cell-free clostridial neurotoxin assays
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
WO2024069191A1 (en) 2022-09-30 2024-04-04 Ipsen Biopharm Limited Clostridial neurotoxin for use in a treatment of bladder pain syndrome

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022950A (en) * 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US4914075A (en) * 1988-12-05 1990-04-03 Uop Dehydrogenation catalyst composition
CA2076386C (en) 1990-02-26 2003-04-22 David S. Hogness Identification and expression of insect steroid receptor dna sequence
US5364791A (en) 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
CA2135644C (en) 1992-05-14 2009-01-27 Elisabetta Vegeto Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5512459A (en) * 1993-07-20 1996-04-30 Bionebraska, Inc. Enzymatic method for modification or recombinant polypeptides
US7037680B2 (en) * 1993-09-21 2006-05-02 The United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
ES2138740T3 (es) * 1994-05-31 2000-01-16 Allergan Inc Modificacion de toxinas de clostridium utilizadas como proteinas de transporte.
US5962637A (en) * 1994-06-03 1999-10-05 Microbiological Research Authority Toxin assay
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
WO1998020135A2 (en) * 1996-11-06 1998-05-14 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Protease-activatable pseudomonas exotoxin a-like proproteins
US5965699A (en) 1996-11-06 1999-10-12 The United States Of America As Represented By The Secretary Of The Army Assay for the proteolytic activity of serotype a from clostridium botulinum
AU1818299A (en) * 1997-12-10 1999-06-28 Washington University Anti-pathogen system and methods of use thereof
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US6461834B1 (en) * 1998-11-06 2002-10-08 Bionebraska, Inc. Clostripain catalyzed amidation of peptides
US6776990B2 (en) * 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
IL129427A0 (en) * 1999-04-13 2000-02-17 Yeda Res & Dev Preparation of biologically active molecules
US20090018081A1 (en) * 1999-08-25 2009-01-15 Allergan, Inc. Activatable clostridial toxins
US7740868B2 (en) * 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
CA2380457A1 (en) * 1999-08-25 2001-03-01 Allergan Sales, Inc. Activatable recombinant neurotoxins
US20080032931A1 (en) * 1999-08-25 2008-02-07 Steward Lance E Activatable clostridial toxins
US20030180289A1 (en) 1999-09-23 2003-09-25 Foster Keith Alan Inhibition of secretion from non-neuronal cells
US6500436B2 (en) 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
JP2002026456A (ja) * 2000-06-30 2002-01-25 Toshiba Corp 半導体装置、半導体レーザ及びその製造方法並びにエッチング方法
US20040219619A1 (en) * 2000-07-21 2004-11-04 Ester Fernandez-Salas Methods of identifying compounds that alter toxin persistence and/or protease activity
WO2002025284A2 (en) 2000-09-25 2002-03-28 U.S. Medical Research Institute Of Infectious Diseases High-throughput assays for the proteolytic activities of clostridial neurotoxins
US6831059B2 (en) * 2000-10-20 2004-12-14 Allergan, Inc. Compositions and methods for treating gonadotrophin related illnesses
US7273722B2 (en) * 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US6787517B1 (en) * 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
US7374896B2 (en) * 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
US7332567B2 (en) * 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US7208285B2 (en) * 2001-08-28 2007-04-24 Allergan, Inc. Fret protease assays for botulinum serotype A/E toxins
US6504006B1 (en) * 2001-10-12 2003-01-07 Nancy Rose Shine Substrate peptides and assays for detecting and measuring proteolytic activity of serotype A neurotoxin from clostridium botulinum
US7022329B2 (en) 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
EP1513945A4 (de) * 2002-05-24 2008-12-24 Restoragen Inc Verfahren zur universellen enzymatischen herstellung bioaktiver peptide
US20040018589A1 (en) * 2002-07-25 2004-01-29 Jun Zhong Method for producing biologically active botulinum neurotoxins through recombinant DNA technique
US7183066B2 (en) * 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
GB0321344D0 (en) * 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
US20060009831A1 (en) 2003-11-07 2006-01-12 Lilip Lau Cardiac harness having leadless electrodes for pacing and sensing therapy
JP5178009B2 (ja) * 2003-12-19 2013-04-10 ウィスコンシン アルムニ リサーチ ファンデイション ボツリヌス神経毒素検出のための方法および複合体
WO2005072159A2 (en) * 2004-01-05 2005-08-11 Biotech Studio, Llc Biotherapeutics, diagnostics and research reagents
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7825233B2 (en) 2004-06-30 2010-11-02 Allergan, Inc. Optimizing expression of active Botulinum Toxin type E
JP4853607B2 (ja) 2004-07-09 2012-01-11 セイコーエプソン株式会社 薄膜トランジスタの製造方法
JP3773058B2 (ja) 2004-07-20 2006-05-10 コナミ株式会社 ゲーム装置、ゲーム装置の制御方法及びプログラム
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
EP1773874B1 (de) 2004-08-04 2012-10-24 Allergan, Inc. Optimierung der expression von aktivem botulinumtoxin a
US7219596B2 (en) 2004-08-19 2007-05-22 Carrier Commerical Refrigeration, Inc. Coffee brewer with loading and ejection mechanism for a coffee cartridge
EP1784420B1 (de) * 2004-09-01 2008-12-03 Allergan, Inc. Abbaubare clostridientoxine
US7399607B2 (en) * 2004-09-22 2008-07-15 Allergan, Inc. Fluorescence polarization assays for determining clostridial toxin activity
JP4994241B2 (ja) * 2004-11-22 2012-08-08 ニューヨーク・ユニバーシティ 遺伝子操作されたクロストリジウム遺伝子、操作された遺伝子によりコードされるタンパク質、およびその使用
CA2595115C (en) * 2004-12-01 2014-01-21 Health Protection Agency Fusion proteins for treating, preventing or ameliorating pain
WO2006059105A2 (en) 2004-12-01 2006-06-08 Health Protection Agency Non-cytotoxic Protein Conjugates
WO2006099590A2 (en) * 2005-03-15 2006-09-21 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
DK2154151T3 (da) * 2005-09-19 2011-09-05 Allergan Inc Clostridiumtoksinaktiverbare clostridiumtoksiner
EP2038298A2 (de) * 2006-07-11 2009-03-25 Allergan, Inc. Modifizierte clostridientoxine mit verbesserten translokationsfähigkeiten und geänderter targeting-aktivität für clostridientoxin-targetzellen

Also Published As

Publication number Publication date
JP5134540B2 (ja) 2013-01-30
AU2006339490A1 (en) 2007-10-25
ES2369558T3 (es) 2011-12-01
EP2154151B1 (de) 2011-08-03
ES2341892T5 (es) 2019-03-27
WO2008008082A2 (en) 2008-01-17
JP2009508489A (ja) 2009-03-05
ATE518882T1 (de) 2011-08-15
EP1926744A2 (de) 2008-06-04
EP2377881B1 (de) 2017-04-26
DK2154151T3 (da) 2011-09-05
US20120115205A1 (en) 2012-05-10
EP1926744B1 (de) 2010-04-07
US7815917B2 (en) 2010-10-19
EP2377881A2 (de) 2011-10-19
AU2006339490A8 (en) 2008-08-07
DK1926744T3 (da) 2010-07-05
ES2341892T3 (es) 2010-06-29
EP1926744B2 (de) 2018-10-24
EP2377881A3 (de) 2012-03-07
EP2154151A2 (de) 2010-02-17
DK1926744T4 (en) 2019-01-28
DE602006013481D1 (de) 2010-05-20
US20070166332A1 (en) 2007-07-19
EP2154151A3 (de) 2010-03-10
US20100075396A1 (en) 2010-03-25
AU2006339490B2 (en) 2011-12-08
WO2008008082A3 (en) 2008-05-15
CA2610103A1 (en) 2007-03-19
US7556817B2 (en) 2009-07-07
US20110111479A1 (en) 2011-05-12

Similar Documents

Publication Publication Date Title
ATE463506T1 (de) Mit clostriedientoxin aktivierbare clostridientoxine
ATE416191T1 (de) Abbaubare clostridientoxine
WO2006099590A3 (en) Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
WO2008008803A3 (en) Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
WO2008008805A3 (en) Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
MX369263B (es) Toxinas de clostridium degradables.
WO2007111642A3 (en) Systems , methods , and processes for use in treating subsurface formations
WO2006116122A3 (en) Systems and processes for use in treating subsurface formations
ATE523206T1 (de) Anthrax-impfstoff
ATE530669T1 (de) Markierte mikroorganismen und entsprechende markierungsverfahren
WO2008051299A3 (en) Systems and processes for use in treating subsurface formations
JP2009508489A5 (de)
ATE531387T1 (de) Nahtlinien-verabreichungstechnik mit botulinustoxinen
ATE462443T1 (de) Dehnungsstreifenbehandlung mit botulinumtoxin
NO20075119L (no) Nedbrytbare geler for anvendelse i soneisolering
ITRM20040447A1 (it) Sistema di fornitura di seminari interattivi, e relativo metodo.
PL383715A1 (pl) Amidy kwasu 3-arylo-3-hydroksy-2-amino-propionowego, amidy kwasu 3-heteroarylo-3-hydroksy-2-amino-propionowego i ich związki pokrewne posiadające aktywność przeciwbólową i/lub pobudzającą odporność
ATE491374T1 (de) Eckstück für eine matratze sowie matratze und entsprechendes herstellungsverfahren
PT1492561E (pt) Metodo para tratar disturbios da glandula mamaria
EA200870144A1 (ru) Способ борьбы с водорослевым загрязнением воды
BRPI0414370A (pt) enzimas modificadas, processos para produzir enzimas modificadas e usos das mesmas
ATE357967T1 (de) Emulsionen mit oberflächenmodifizierten organischen molekülen
BR0300922B1 (pt) sistema para utilizaÇço no controle da operaÇço de um poÇo de produÇço de hidrocarboneto.
BRPI0514836A (pt) uso de toxina botulìnica para tratamento de uma deformidade da nádega
BRPI0509478A (pt) tratamento de ferida por pressão

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties